Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

NCT05789043 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Acral Melanoma

Interventions

DRUG: camrelizumab+apatinib+TMZ
DRUG: camrelizumab+apatinib
DRUG: camrelizumab

Sponsor

Peking University Cancer Hospital & Institute